Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9227674 | Journal of Allergy and Clinical Immunology | 2005 | 8 Pages |
Abstract
On the basis of a model treatment strategy, we estimate that allocating subjects to ICS therapy on the basis of changes in sputum eosinophil counts after a trial discontinuation could allow 48% of subjects with mild-to-moderate asthma to discontinue ICS therapy without an increased risk of asthma deterioration over a period of at least 14 weeks.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Aaron MD, Stephen C. MD, John V. MD, ChB, Michael E. MD, MMSc, Homer A. MD, Vernon M. PhD, Timothy J. DO, Emily MD, Monica MD, Frank MD, Robert F. MD, Richard J. MD, Gene R. MD, MPH, Stephen P. MD, PhD, Christine A. PharmD, Stanley J. MD, Elliot MD,